Breast Cancer Research and Treatment

, Volume 139, Issue 3, pp 811–819 | Cite as

Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands

  • A. Font-Gonzalez
  • L. Liu
  • A. C. Voogd
  • M. K. Schmidt
  • J. A. Roukema
  • J. W. W. Coebergh
  • E. de Vries
  • I. Soerjomataram


To compare overall survival between women with unilateral breast cancer (UBC) and contralateral breast cancer (CBC). Women with UBC (N = 182,562; 95 %) and CBC (N = 8,912; 5 %) recorded in the Netherlands Cancer Registry between 1989 and 2008 were included and followed until 2010. We incorporated CBC as a time-dependent covariate to compute the overall mortality rate ratio between women with CBC and UBC. Prognostic factors for overall death were examined according to age at first breast cancer. Women with CBC exhibited a 30 % increase in overall mortality (Hazard Ratio (HR), 95 % Confidence Interval: 1.3, 1.3–1.4) compared with UBC, decreasing with rising age at diagnosis of first breast cancer (<50 years: 2.3, 2.2–2.5 vs. ≥70 years: 1.1, 1.0–1.1). Women older than 50 years at CBC diagnosis and diagnosed 2–5 years after their first breast cancer exhibited a 20 % higher death risk (1.2, 1.0–1.3) compared to those diagnosed within the first 2 years. In women younger than 50 years, the HR was significantly lower if the CBC was diagnosed >5 years after the first breast cancer (0.7, 0.5–0.9). The prognosis for women with CBC significantly improved over time (2004–2008: 0.6, 0.5-0.7 vs. 1989–1993). Women with CBC had a lower survival compared to women with UBC, especially those younger than 50 years at first breast cancer diagnosis. A tailored follow-up strategy beyond current recommendations is needed for these patients who, because of their age and absence of known familial risk, are currently not invited for population-based screening.


Breast neoplasms Mortality Prognosis Retrospective cohort studies Second primary 



The authors thank the registration clerks and data managers at the Comprehensive Cancer Centres for their collection of data for the Netherlands Cancer Registry as well as the scientific staff of the Netherlands Cancer Registry. This study is part of a project funded by the Dutch Cancer Society (KWF): The increasing burden of second primary cancers in the Netherlands: trend in incidence, survival and causes-of-death since 1970 (EMCR 2008-4132). Anna Font-Gonzalez was funded through an Academy Assistantship from the KNAW (Royal Netherlands Academy of Arts and Sciences).

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, Bray F (2012) Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 380:1840–1850. doi: 10.1016/S0140-6736(12)60919-2 Google Scholar
  2. 2.
    Netherlands Cancer Registry (NCR) (2012) Most common types of cancer. Accessed 21 June 2012
  3. 3.
    Louwman WJ, Voogd AC, van Dijck J, Nieuwenhuijzen GA, Ribot J, Pruijt JF, Coebergh JW (2008) On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975–2004: a long-term population-based study in southeastern Netherlands. Cancer Causes Control 19:97–106PubMedCrossRefGoogle Scholar
  4. 4.
    Karim-Kos HE, Kiemeney LALM, Louwman MWJ, Coebergh JWW, de Vries E (2012) Progress against cancer in the Netherlands since the late 1980s: an epidemiological evaluation. Int J Cancer 130:2981–2989PubMedCrossRefGoogle Scholar
  5. 5.
    Nationwide breast cancer screening programme fully implemented in the Netherlands, Fracheboud J, de Koning HJ, Boer R, Groenewoud JH, Verbeek ALM, Broeders MJM, van Ineveld BM, Hendriks JHCL, de Bruyn AE, Holland R, van der Maas PJ (2001) Nationwide breast cancer screening programme fully implemented in the Netherlands. Breast 10:6–11PubMedCrossRefGoogle Scholar
  6. 6.
    Bray F, Jemal A, Grey N, Ferlay J, Forman D (2012) Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol 13:790–801. doi: 10.1016/S1470-2045(12)70211-5 PubMedCrossRefGoogle Scholar
  7. 7.
    Soerjomataram I, Louwman WJ, Lemmens VEPP, de Vries E, Klokman WJ, Coebergh JWW (2005) Risks of second primary breast and urogenital cancer following female breast cancer in the south of The Netherlands, 1972–2001. Eur J Cancer 41:2331–2337PubMedCrossRefGoogle Scholar
  8. 8.
    Holmberg L, Adami H, Ekbom A, Bergstram R, Sandstram A, Lindgren A (1988) Prognosis in bilateral breast cancer. Effects of time interval between first and second primary tumours. Br J Cancer 58:191–194PubMedCrossRefGoogle Scholar
  9. 9.
    Brenner H, Engelsmann B, Stegmaier C, Ziegler H (1993) Clinical epidemiology of bilateral breast cancer. Cancer 72:3629–3635PubMedCrossRefGoogle Scholar
  10. 10.
    Gajalakshmi C, Shanta V, Hakama M (1999) Survival from contralateral breast cancer. Breast Cancer Res Treat 58:115–122PubMedCrossRefGoogle Scholar
  11. 11.
    Abdalla I, Thisted R, Heimann R (2000) The impact of contralateral breast cancer on the outcome of breast cancer patients treated by mastectomy. Cancer J 6:266–272PubMedGoogle Scholar
  12. 12.
    Jobsen JJ, Jvd Palen, Ong F, Meerwaldt JH (2003) Synchronous, bilateral breast cancer: prognostic value and incidence. Breast 12:83–88PubMedCrossRefGoogle Scholar
  13. 13.
    Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, Dickman PW, Hall P (2007) Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol 25:4210–4216PubMedCrossRefGoogle Scholar
  14. 14.
    Schaapveld M, Visser O, Louwman W, Willemse PH, de Vries EG, van der Graaf WT, Otter R, Coebergh JW, van Leeuwen FE (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189–197PubMedCrossRefGoogle Scholar
  15. 15.
    Kuo WH, Yen AM, Lee PH, Chen KM, Wang J, Chang KJ, Chen TH, Tsau HS (2009) Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. Br J Cancer 100:563–570PubMedCrossRefGoogle Scholar
  16. 16.
    Vichapat V, Garmo H, Holmberg L, Fentiman IS, Tutt A, Gillett C, Lüchtenborg M (2011) Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses. Breast Cancer Res Treat 130:609–618PubMedCrossRefGoogle Scholar
  17. 17.
    Schwentner L, Wolters R, Wischnewsky M, Kreienberg R, Wöckel A (2012) Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients. Breast 21:171–177PubMedCrossRefGoogle Scholar
  18. 18.
    Heron D, Komarnicky L, Hyslop T, Schwartz G, Mansfield C (2000) Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer 88:2739–2750PubMedCrossRefGoogle Scholar
  19. 19.
    Takahashi H, Watanabe K, Takahashi M, Taguchi K, Sasaki F, Todo S (2005) The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer. Breast Cancer 12:196–202PubMedCrossRefGoogle Scholar
  20. 20.
    Verkooijen HM, Chatelain V, Fioretta G, Vlastos G, Rapiti E, Sappino AP, Bouchardy C, Chappuis PO (2007) Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat 105:347–357PubMedCrossRefGoogle Scholar
  21. 21.
    Irvine T, Allen DS, Gillett C, Hamed H, Fentiman IS (2009) Prognosis of synchronous bilateral breast cancer. Br J Surg 96:376–380PubMedCrossRefGoogle Scholar
  22. 22.
    Mose S, Adamietz IA, Thilmann C, Saran F, Bernhard M, Pahnke R, Böttcher HD (1997) Bilateral breast carcinoma versus unilateral disease: review of 498 patients. Am J Clin Oncol 20:541–545PubMedCrossRefGoogle Scholar
  23. 23.
    Michowitz M, Noy S, Lazebnik N, Aladjem D (1985) Bilateral breast cancer. J Surg Oncol 30:109–112PubMedCrossRefGoogle Scholar
  24. 24.
    Gustafsson A, Tartter P, Brower S, Lesnick G (1994) Prognosis of patients with bilateral carcinoma of the breast. J Am Coll Surg 178:111–116PubMedGoogle Scholar
  25. 25.
    Skowronek J, Piotrowski T (2002) Bilateral breast cancer. Neoplasma 49:49–54PubMedGoogle Scholar
  26. 26.
    Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, Meijer GA (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29:19–24PubMedGoogle Scholar
  27. 27.
    Schouten LJ, Jager JJ, van den Brandt PA (1993) Quality of cancer registry data: a comparison of data provided by clinicians with those of registration personnel. Br J Cancer 68:974–977PubMedCrossRefGoogle Scholar
  28. 28.
    Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA, Jager JJ (1993) Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 22:369–376PubMedCrossRefGoogle Scholar
  29. 29.
    International Association of Cancer Registries (IACR) (2005) International rules for multiple primary cancers. Asian Pac J Cancer Prev 6:104–106Google Scholar
  30. 30.
    Rothman KJ, Greenland S (1998) Cohort studies. In: Rothman KJ, Greenland S (eds) Modern epidemiology, 2nd edn. Lippincott-Raven, Philadelphia, pp 79–91Google Scholar
  31. 31.
    Maaskant AJ, van de Poll-Franse LV, Voogd AC, Coebergh JW, Tutein Nolthenius-Puylaert MC, Nieuwenhuijzen GA (2009) Stage migration due to introduction of the sentinel node procedure: a population-based study. Breast Cancer Res Treat 113:173–179PubMedCrossRefGoogle Scholar
  32. 32.
    Janssen-Heijnen ML, van Steenbergen LN, Voogd AC, Nijhuis PH, Poortmans PH, Coebergh JW (2012) Long-term excess mortality for survivors of breast cancer in the Netherlands 2013 (submitted)Google Scholar
  33. 33.
    Alkner S, Bendahl P, Fernö M, Manjer J, Rydénm L (2011) Prediction of outcome after diagnosis of metachronous contralateral breast cancer. BMC Cancer 11:114. doi: 10.1186/1471-2407-11-114 PubMedCrossRefGoogle Scholar
  34. 34.
    Neta G, Anderson WF, Gilbert E, Berrington A (2012) Variation in the risk of radiation-related contralateral breast cancer by histology and estrogen receptor expression in SEER. Breast Cancer Res Treat 131:1021–1027PubMedCrossRefGoogle Scholar
  35. 35.
    Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101:1058–1065PubMedCrossRefGoogle Scholar
  36. 36.
    Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, Trichopoulos D, Adami HO, Hall P (2005) Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol 6:377–382PubMedCrossRefGoogle Scholar
  37. 37.
    Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS One 4:e7695. doi: 10.1371/journal.pone.0007695 PubMedCrossRefGoogle Scholar
  38. 38.
    Vichapat V, Garmo H, Holmqvist M, Liljegren G, Wärnberg F, Lambe M, Fornander T, Adolfsson J, Lüchtenborg M, Holmberg L (2012) Tumour stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study. J Clin Oncol 30:3478–3484PubMedCrossRefGoogle Scholar
  39. 39.
    Chaudary MA, Millis RR, Hoskins EO, Halder M, Bulbrook RD, Cuzick J, Hayward JL (1984) Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg 71:711–714PubMedCrossRefGoogle Scholar
  40. 40.
    Janschek E, Kandioler-Eckersberger D, Ludwig C, Kappel S, Wolf B, Taucher S, Rudas M, Gnant M, Jakesz R (2001) Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat 67:1–8PubMedCrossRefGoogle Scholar
  41. 41.
    Brommesson S, Jönsson G, Strand C, Grabau D, Malmström P, Ringnér M, Fernö M, Hedenfalk I (2008) Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs. BMC Clin Pathol 8:6PubMedCrossRefGoogle Scholar
  42. 42.
    Vichapat V, Garmo H, Holmberg L, Fentiman IS, Tutt A, Gillett C, Lüchtenborg M (2012) Patterns of metastasis in women with metachronous contralateral breast cancer. Br J Cancer 107:221–223PubMedCrossRefGoogle Scholar
  43. 43.
    Eaker S, Dickman PW, Bergkvist L, Holmberg L (2006) Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden. PLoS Med 3:e25. doi: 10.1371/journal.pmed.0030025 PubMedCrossRefGoogle Scholar
  44. 44.
    Comprehensive Cancer Centre of the Netherlands (IKNL) (2012) Mammacarcinoom: Aanbevelingen nacontrole (Breast cancer: recommendations for surveillance). Accessed 22 July 2012
  45. 45.
    Houssami N, Abraham LA, Miglioretti DL, Sickles EA, Kerlikowske K, Buist DS, Geller BM, Muss HB, Irwig L (2011) Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. JAMA 305:790–799PubMedCrossRefGoogle Scholar
  46. 46.
    Setz-Pels W, Duijm LE, Groenewoud JH, Voogd AC, Jansen FH, Hooijen MJ, Louwman MW (2011) Detection of bilateral breast cancer at biennial screening mammography in the Netherlands: a population-based study. Radiology 260:357–363PubMedCrossRefGoogle Scholar
  47. 47.
    Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, Böhm-Vélez M, Mahoney MC, Evans WP III, Larsen LH, Morton MJ, Mendelson EB, Farria DM, Cormack JB, Marques HS, Adams A, Yeh NM, Gabrielli G (2012) Detection of breast cancer with addition of annual screening utrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 307:1394–1404PubMedCrossRefGoogle Scholar
  48. 48.
    Tan MB, Bleiker EM, Menke-Pluymers MB, Van Gool AR, van Dooren S, Van Geel BN, Tilanus-Linthorst MM, Bartels KC, Klijn JG, Brekelmans CT, Seynaeve C (2009) Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy. Hered Cancer Clin Pract 7:6PubMedCrossRefGoogle Scholar
  49. 49.
    van Schoor G, Broeders MJM, Paap E, Otten JDM, den Heeten GJ, Verbeek ALM (2008) A rational for starting breast cancer screening under age 50. Ann Oncol 19:1208–1209PubMedCrossRefGoogle Scholar
  50. 50.
    Soerjomataram I, Pukkala E, Brenner H, Coebergh JW (2008) On the avoidability of breast cancer in industrialized societies: older mean age at first birth as an indicator of excess breast cancer risk. Breast Cancer Res Treat 111:297–302PubMedCrossRefGoogle Scholar
  51. 51.
    Louwman WJ, Janssen-Heijnen ML, Houterman S, Voogd AC, van der Sangen MJ, Nieuwenhuijzen GA, Coebergh JW (2005) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41:779–785PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • A. Font-Gonzalez
    • 1
    • 2
  • L. Liu
    • 1
  • A. C. Voogd
    • 3
    • 4
  • M. K. Schmidt
    • 5
  • J. A. Roukema
    • 6
  • J. W. W. Coebergh
    • 1
    • 3
  • E. de Vries
    • 1
    • 2
  • I. Soerjomataram
    • 7
  1. 1.Department of Public HealthErasmus University Medical CenterRotterdamThe Netherlands
  2. 2.Netherlands Institute for Health Sciences (NIHES)RotterdamThe Netherlands
  3. 3.Comprehensive Cancer Centre South (IKZ)EindhovenThe Netherlands
  4. 4.Department of EpidemiologyUniversity of MaastrichtMaastrichtThe Netherlands
  5. 5.Division of Molecular PathologyNetherlands Cancer InstituteAmsterdamThe Netherlands
  6. 6.Department of SurgerySt Elisabeth HospitalTilburgThe Netherlands
  7. 7.Section of Cancer InformationInternational Agency for Research on CancerLyonFrance

Personalised recommendations